Abstract:Testing of drug effects and cytotoxicity by using cultured cells has been widely performed as an alternative to animal testing. However, the estimation of pharmacokinetics by conventional cell-based assay methods is difficult because of the inability to evaluate multiorgan effects. An important challenge in the field is to mimic the organ-to-organ network in the human body by using a microfluidic network connecting small-scale tissues based on recently emerging MicroTAS (Micro Total Analysis Systems) technology for prediction of pharmacokinetics. Here, we describe an on-chip small intestine-liver coupled model for pharmacokinetic studies. To construct an in vitro pharmacokinetic model that appropriately models in vivo conditions, physiological parameters such as the structure of internal circulation, volume ratios of each organ, and blood flow ratio of the portal vein to the hepatic artery were mimicked using microfluidic networks. To demonstrate interactions between organs in vitro in pharmacokinetic studies, Caco-2, HepG2, and A549 cell cultures were used as organ models of the small intestine, liver, and lung, respectively, and connected to each other through a microporous membrane and microchannels to prepare a simple model of a physiological organ-to-organ network. The on-chip organ model assay using three types of substrate-epirubicine (EPI), irinotecan (CPT-11), and cyclophosphamide (CPA)-were conducted to model the effects of orally administered or biologically active anticancer drugs. The result suggested that the device can replicate physiological phenomena such as activity of the anticancer drugs on the target cells. This microfluidic device can thus be used as an in vitro organ model to predict the pharmacokinetics of drugs in the human body and may thus provide not only an alternative to animal testing but also a method of obtaining parameters for in silico models of physiologically based pharmacokinetics.

Microfluidic models in liver drug metabolism research

Synergistic Modulation of a Tunable Microenvironment to Fabricate a Liver Fibrosis Chip for Drug Testing.

Hydrogel Microfluidic‐based Liver‐on‐a‐chip: Mimicking the Mass Transfer and Structural Features of Liver

Engineered Liver-on-a-Chip Platform to Mimic Liver Functions and Its Biomedical Applications: A Review

Dynamic Liver Chip Based on Well-Coupled Microfluidics: An Accurate NASH Model for Drug Evaluation

A microvascularized in vitro liver model for disease modeling and drug discovery

Experimental liver models: From cell culture techniques to microfluidic organs‐on‐chip

Construction of in vitro liver-on-a-chip models and application progress

Construction and Application of 3D Microfluidic Liver-On-A-Chip

Recent advances in the development of in vitro liver models for hepatotoxicity testing

On-Chip Construction of Liver Lobule-like Microtissue and Its Application for Adverse Drug Reaction Assay.

Advanced Liver-on-a-Chip Model for Evaluating Drug Metabolism and Hepatotoxicity

Development of novel tools for the in vitro investigation of drug-induced liver injury

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

In vitro and in silico liver models: Current trends, challenges and opportunities

A Cell Lines Derived Microfluidic Liver Model for Investigation of Hepatotoxicity Induced by Drug-Drug Interaction

A Simplified 3D Liver Microsphere Tissue Culture Model for Hepatic Cell Signaling and Drug-Induced Hepatotoxicity Studies

Advantages,disadvantages and applications of in vitro hepatic metabolic models

A 3D bio-printed spheroids based perfusion in vitro liver on chip for drug toxicity assays

An On-Chip Small Intestine–Liver Model for Pharmacokinetic Studies